New drug aims to ease daily struggles of myasthenia gravis
NCT ID NCT07673627
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests an experimental drug called empasiprubart in people with a specific type of generalized myasthenia gravis (gMG) who have AChR antibodies. The goal is to see if the drug is safe and can improve symptoms like muscle weakness that affect daily activities. Participants receive either empasiprubart or a placebo by intravenous infusion, and researchers track side effects and changes in symptom scores over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empasiprubart
What this could lead to
If successful, this could offer a new treatment option for people with generalized myasthenia gravis, potentially improving daily function and quality of life.
What could go wrong
This is an early Phase 2a study with only 40 participants, so results may not apply to all patients. The drug may cause side effects or fail to show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GMG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••